GTBP Net Cash Flow from Operations from 2010 to 2024

GTBP Stock  USD 4.43  0.06  1.37%   
Check GT Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GTBP main balance sheet or income statement drivers, such as Depreciation And Amortization of 275.9 K, Interest Expense of 202.3 K or Selling General Administrative of 8.8 M, as well as many exotic indicators such as Price To Sales Ratio of 2.3 K, Dividend Yield of 0.0 or Price Book Value Ratio of 1.31. GTBP financial statements analysis is a perfect complement when working with GT Biopharma Valuation or Volatility modules.
  
This module can also supplement GT Biopharma's financial leverage analysis and stock options assessment as well as various GT Biopharma Technical models . Check out the analysis of GT Biopharma Correlation against competitors.
To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.

About GT Biopharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include GT Biopharma income statement, its balance sheet, and the statement of cash flows. GT Biopharma investors use historical funamental indicators, such as GT Biopharma's Net Cash Flow from Operations, to determine how well the company is positioned to perform in the future. Although GT Biopharma investors may use each financial statement separately, they are all related. The changes in GT Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on GT Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on GT Biopharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in GT Biopharma. Please read more on our technical analysis and fundamental analysis pages.
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager fusion protein immune cell engager technology platform. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California. GT Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether GT Biopharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GTBP Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Gt Biopharma Stock. Highlighted below are key reports to facilitate an investment decision about Gt Biopharma Stock:
Check out the analysis of GT Biopharma Correlation against competitors.
To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.
Note that the GT Biopharma information on this page should be used as a complementary analysis to other GT Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Complementary Tools for GTBP Stock analysis

When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fundamental Analysis
View fundamental data based on most recent published financial statements
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Is GT Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GT Biopharma. If investors know GTBP will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GT Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(9.12)
Return On Assets
(0.55)
Return On Equity
(0.79)
The market value of GT Biopharma is measured differently than its book value, which is the value of GTBP that is recorded on the company's balance sheet. Investors also form their own opinion of GT Biopharma's value that differs from its market value or its book value, called intrinsic value, which is GT Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GT Biopharma's market value can be influenced by many factors that don't directly affect GT Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GT Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if GT Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GT Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.